Last reviewed · How we verify
Engelhard Arzneimittel GmbH & Co.KG — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Cineol | Cineole | marketed | cineole | Other | ||
| Nasal Decongestant | Nasal Decongestant | marketed | Sympathomimetic decongestant | Alpha-adrenergic receptors (likely alpha-1) | Otolaryngology / Respiratory | |
| Ivy Leaves Cough Liquid | Ivy Leaves Cough Liquid | marketed | Herbal expectorant | Respiratory |
Therapeutic area mix
- Other · 1
- Otolaryngology / Respiratory · 1
- Respiratory · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Engelhard Arzneimittel GmbH & Co.KG:
- Engelhard Arzneimittel GmbH & Co.KG pipeline updates — RSS
- Engelhard Arzneimittel GmbH & Co.KG pipeline updates — Atom
- Engelhard Arzneimittel GmbH & Co.KG pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Engelhard Arzneimittel GmbH & Co.KG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/engelhard-arzneimittel-gmbh-co-kg. Accessed 2026-05-17.